Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher toutes les espèces
Afficher tous les synonymes
Sélectionnez vos espèces et l'application
anti-Human TCF7 Anticorps:
anti-Mouse (Murine) TCF7 Anticorps:
anti-Rat (Rattus) TCF7 Anticorps:
Vous arrivez à notre recherche pré-filtrée.
We demonstrated that the AR-miR-1 (Montrer FSD1 Anticorps) axis negatively regulates the novel oncogenic factor, TCF7. Dysregulation of TCF7 promoted a survival advantage and resistance to androgen deprivation, suggesting its therapeutic potential for castration-resistant prostate cancer.
High expression of TCF7 is associated with osteosarcoma.
Findings indicate that breast cancer cells with a hyperactive AF1q (Montrer MLLT11 Anticorps)/TCF7/CD44 (Montrer CD44 Anticorps) regulatory axis in the primary sites may represent "metastatic founder cells" which have invasive properties.
TCF7 plays critical roles in lung diseases [review]
Tcf7 levels are lower in islets taken from patients with type 2 diabetes. Knockdown of TCF7 in islets impairs the cytoprotective respo (Montrer GIP Anticorps)nsiveness to GIP and enhances the magnitude of apoptotic injury.
Capsaicin-induced apoptosis in pancreatic cancer cells was associated with inhibition of beta-catenin (Montrer CTNNB1 Anticorps) signaling due to the dissociation of beta-catenin (Montrer CTNNB1 Anticorps)/TCF-1 (Montrer HNF1A Anticorps) complex and the process was orchestrated by STAT-3 (Montrer STAT3 Anticorps).
we show that TCF7 is a direct target of miR (Montrer MLXIP Anticorps)-34a in prostate cancer that has metastasized to the bone
induction of expression activates the Wnt (Montrer WNT2 Anticorps) signaling pathway, leading to priming of liver cancer stem cells self-renewal and tumor propagation
RUNX2 (Montrer RUNX2 Anticorps) signaling pathways with their partners TCF7 and FGFR1 (Montrer FGFR1 Anticorps)/2 may not be involved in CCD (Montrer RUNX2 Anticorps) pathogenesis
Results suggest ivermectin as therapeutic WNT protein-TCF (Montrer HNF4A Anticorps) transcription factor pathway response blocker to treat WNT (Montrer WNT2 Anticorps)-TCF (Montrer HNF4A Anticorps)-dependent diseases including multiple cancers.
This is attributed in part to ineffective repression of Tcf1 (Montrer HNF1A Anticorps) expression in knockout T cells, as DNMT3a (Montrer DNMT3A Anticorps) localizes to the Tcf7 promoter and catalyzes its de novo methylation in early effector WT CD8 (Montrer CD8A Anticorps)(+) T cells. These data identify DNMT3a (Montrer DNMT3A Anticorps) as a crucial regulator of CD8 (Montrer CD8A Anticorps)(+) early effector cell differentiation and effector versus memory fate decisions.
The balance between CD4 (Montrer CD4 Anticorps)(+) cytotoxic T cell and follicular helper T(Tfh) differentiation heavily depends on the class of infecting virus and is jointly regulated by the Tfh-related transcription factors Bcl6 (Montrer BCL6 Anticorps) and Tcf7 (encoding TCF-1 (Montrer HNF1A Anticorps)) and by the expression of the inhibitory receptors PD-1 (Montrer PDCD1 Anticorps) and LAG3 (Montrer LAG3 Anticorps).
data reveal that T cell factor 1 (Tcf1) long and short isoforms have distinct, yet complementary, functions and may represent an evolutionarily conserved means to ensure proper programming of CD8 (Montrer CD8A Anticorps)(+) and CD4 (Montrer CD4 Anticorps)(+) T cell responses to viral infection
Tcf7 levels are lower in islets taken from diabetic mice. Knockdown of TCF7 in islets impairs the cytoprotective responsiveness to GIP (Montrer GIP Anticorps) and enhances the magnitude of apoptotic injury.
TCF-1-deficient CD4+ CD8+ double positive thymocytes fail to undergo TCR alpha Valpha14-Jalpha18 rearrangement and produce significantly fewer Natural killer T cells.
The data suggest that miR (Montrer MLXIP Anticorps)-24 participates in osteogenic differentiation by targeting and regulating Tcf-1 (Montrer HNF1A Anticorps) expression in osteoblastic cells.
this study proposes a regulatory role for TCF7 in limiting access to the Treg lineage
Our results support a critical role for miR (Montrer MLXIP Anticorps)-22-3p and its target, Tcf7, in the pathogenesis of diabetes by upregulating gluconeogenesis.
TCF-1 (Montrer HNF1A Anticorps) was essential for both the initiation of T(FH) differentiation and the effector function of differentiated T(FH) cells during acute viral infection. TCF-1 (Montrer HNF1A Anticorps) promoted Bcl-6 (Montrer BCL6 Anticorps) expression but repressed Blimp1 (Montrer PRDM1 Anticorps) expression.
Chromatin immunoprecipitation sequencing revealed the transcription factor Tcf7 and the chemokine receptor Ccr7 (Montrer CCR7 Anticorps) as Foxo1 (Montrer FOXO1 Anticorps)-bound target genes, which have critical functions in central-memory T cell differentiation and trafficking.
The protein encoded by this gene is a transcriptional activator that plays an important role in lymphocyte differentiation. This gene is expressed predominantly in T-cells. The encoded protein can bind an enhancer element and activate the CD3E gene, and it also may repress the CTNNB1 and TCF7L2 genes through a feedback mechanism. Several transcript variants encoding different isoforms have been found for this gene.
T-cell-specific transcription factor 1
, transcription factor 7
, T cell factor-1
, T-cell factor 1
, transcription factor 7, T-cell specific
, transcription factor 7 (T-cell specific, HMG-box)
, T-cell factor 7
, T cell-specific transcription factor 1
, transcription factor 7 (T-cell specific, HMG-box) S homeolog
, transcription factor 7 S homeolog